Mankind Pharma Limited has intimated the stock exchanges about an upcoming Board of Directors meeting scheduled for Monday, October 26, 2026. The primary agenda of the meeting is to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026.
The disclosure is made under Regulation 29 and Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").
In continuation of the company's earlier intimation dated September 25, 2026 regarding the closure of the trading window under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed until October 28, 2026.
The notice has been uploaded on the company's website at www.mankindpharma.com. The communication is signed by Hitesh Kumar Jain, Company Secretary & Compliance Officer of Mankind Pharma Limited, with a digital signature timestamp of October 8, 2026 at 17:18:12 IST.